Mitsui & Co., Ltd. has participated as a lead investor in a Series B round financing of Koios Medical, Inc. (Koios), a U.S.-based healthcare technology and digital medicine company.

This investment was facilitated by Mitsui’s wholly-owned subsidiary, MBK Healthcare Management (MHM), which is Mitsui’s dedicated healthcare operating platform, Mitsui said in a statement on Tuesday.

It is noted that MHM is also the largest shareholder of IHH Healthcare Berhad, a leading premium healthcare provider operating 80 hospitals in 10 countries with more than 15,000 licensed beds.

“Today, the global healthcare industry is facing many difficulties, such as rising medical costs and a shortage of healthcare workers,

“At Mitsui, we believe that these issues can be addressed by harnessing the potential of untapped data within the healthcare system, as well as through active collaboration between traditional healthcare stakeholders and new businesses on cutting edge technological solutions,” said Takeshi Akutsu, Chief Operating Officer of Mitsui’s Wellness Business Unit.

“In line with this belief, both Mitsui and MHM have been actively exploring the health tech start-up space, with the aim of strengthening Mitsui’s healthcare assets and expanding our healthcare data business by investing in innovative start-ups that transform care and harness the power of data within our portfolio,” he added.

With regulatory clearances from the U.S. Food and Drug Administration and CE Marks, Koios develops artificial intelligence (AI)-powered clinical decision support software for radiologists, endocrinologists, and other trained physicians and technicians, which are vendor agnostic solutions that can be integrated into most picture archiving and communication systems (PACS) workstations for breast and thyroid ultrasound analysis and reporting.

Koios’s software aims to empower physicians in their decision-making process, and enhance the patient experience, identify cancers in earlier stages, reduce unnecessary procedures and minimize the stress associated with false positive findings.

“AI-enabled decision support solutions such as Koios’s are increasingly important to alleviate the rising pressures in radiology and healthcare systems worldwide brought on by ageing populations, escalating healthcare costs and a healthcare workforce shortage,” said Takeshi Saito, Managing Director and Chief Executive Officer of MHM.

“Koios’s focus on improving both the physician’s and individual’s experience aligns this investment with Mitsui’s and MHM’s common goal of transforming patient care. MHM aims to facilitate collaborations between Mitsui’s existing portfolio companies and Koios, as well as help Koios expand its presence globally to enable better patient care,” he added.

Mitsui believes it is important to transform the healthcare system into a more patient centric one, and promote the prevention of illnesses and create the environment, in where people can enjoy both physical and mental well-being.

To establish “wellness” fulfilled by three key elements – healthcare, prevention and well-being – Mitsui is pursuing to create various businesses through integrating its tangible assets and digital solutions.

It opines that wellness, the new wealth—We will create a brighter future in which the wellness we offer provides new wealth to people around the world.

Mitsui & Co., Ltd. is a global trading and investment company with a diversified business portfolio that spans approximately 63 countries in Asia, Europe, North, Central & South America, The Middle East, Africa and Oceania.

Mitsui has about 5,500 employees and deploys talent around the globe to identify, develop, and grow businesses in collaboration with a global network of trusted partners.

The firm has built a strong and diverse core business portfolio covering the mineral and metal resources, energy, machinery and infrastructure, and chemicals industries.

Leveraging its strengths, Mitsui has further diversified beyond its core profit pillars to create multifaceted value in new areas, including innovative energy solutions, healthcare and nutrition and through a strategic focus on high-growth Asian markets.

This strategy aims to derive growth opportunities by harnessing some of the world’s main mega-trends: sustainability, health and wellness, digitalization and the growing power of the consumer.

Mitsui has a long heritage in Asia, where it has established a diverse and strategic portfolio of businesses and partners that gives it a strong differentiating edge, provides exceptional access for all global partners to the world’s fastest growing region and strengthens its international portfolio.

Singapore’s Aktivolabs scores $10M capital commitment from Mitsui to fuel global expansion